|
1
|
Orecchia R, Krengli M, Jereczek-Fossa BA,
Franzetti S and Gerard JP: Clinical and research validity of
hadrontherapy with ion beams. Crit Rev Oncol Hematol. 51:81–90.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Finn RS: Development of molecularly
targeted therapies in hepatocellular carcinoma: where do we go now?
Clin Cancer Res. 15:390–397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pommier P, Hu Y, Baron MH, Chapet O and
Balosso J: Particle therapy: carbon ions. Bull Cancer. 97:819–829.
2010.PubMed/NCBI
|
|
4
|
Hamada N, Imaoka T, Masunaga S, et al:
Recent advances in the biology of heavy-ion cancer therapy. J
Radiat Res. 51:365–383. 2010. View Article : Google Scholar
|
|
5
|
Dumont F, Altmeyer A and Bischoff P:
Radiosensitising agents for the radiotherapy of cancer: novel
molecularly targeted approaches. Expert Opin Ther Pat. 19:775–799.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Begg AC, Stewart FA and Vens C: Strategies
to improve radiotherapy with targeted drugs. Nat Rev Cancer.
11:239–253. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abraham RT and Gibbons JJ: The mammalian
target of rapamycin signaling pathway: twists and turns in the road
of cancer therapy. Clin Cancer Res. 13:3109–3114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chiong E, Lee IL, Dadbin A, et al: Effects
of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin
Cancer Res. 17:2863–2873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dancey J: mTOR signaling and drug
development in cancer. Nat Rev Clin Oncol. 7:209–219. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kudo M: mTOR inhibitor for the treatment
of hepatocellular carcinoma. Dig Dis. 29:310–315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gueulette J, Slabbert JP, Bischoff P,
Denis JM, Wambersie A and Jones D: Fast neutrons: Inexpensive and
reliable tool to investigate high-LET particle radiobiology. Rad
Meas. 45:1414–1416. 2010. View Article : Google Scholar
|
|
12
|
Riccardi C and Nicoletti I: Analysis of
apoptosis by propidium iodide staining and flow cytometry. Nature
Protocols. 1:1458–1461. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu B, Wu Y, Shen L, et al: Two-dose-level
confirmatory study of the pharmacokinetics and tolerability of
everolimus in Chinese patients with advanced solid tumors. J
Hematol Oncol. 13:4–3. 2001.PubMed/NCBI
|
|
14
|
Altmeyer A, Jung AC, Ignat M, et al:
Pharmacological enhancement of autophagy induced in a
hepatocellular carcinoma cell line by high-LET radiation.
Anticancer Res. 30:303–310. 2010.PubMed/NCBI
|
|
15
|
Nyfeler B, Bergman P, Triantafellow E, et
al: Relieving autophagy and 4EBP1 from rapamycin resistance. Mol
Cell Biol. 31:2867–2876. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodriguez-Rocha H, Garcia-Garcia A,
Panayiotidis MI and Franco R: DNA damage and autophagy. Mutat Res.
3:158–166. 2011. View Article : Google Scholar
|
|
17
|
Altmeyer A, Ignat M, Denis JM, Messaddeg
N, Gueulette J, Mutter D and Bischoff P: Cell death after high-LET
irradiation in orthotopic human hepatocellular carcinoma in vivo.
In vivo. 25:1–9. 2011.PubMed/NCBI
|
|
18
|
Hada M and Georgakilas AG: Formation of
clustered DNA damage after High-LET irradiation: a review. J Radiat
Res. 49:203–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Benzina S, Altmeyer A, Malek F, et al:
High-LET radiation combined with oxaliplatin induces autophagy in
U-87 glioblastoma cells. Cancer Lett. 264:63–70. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zois CE and Koukourakis MI:
Radiation-induced autophagy in normal and cancer cells: towards
novel cytoprotection and radiosensitization policies? Autophagy.
5:442–450. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Todde V, Veenhuis M and van der Klei IJ:
Autophagy: Principles and significance in health and disease.
Biochim Biophys Acta. 1792:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Wang LX, Pang P, et al:
Tumor-derived autophagosomes vaccine: mechanism of
cross-presentation and therapeutic efficacy. Clin Cancer Res.
17:7047–7057. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeshima T, Chamoto K, Wakita D, et al:
Local radiation therapy inhibits tumor growth through the
generation of tumor-specific CTL: its potentiation by combination
with Th1 cell therapy. Cancer Res. 70:2697–2706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jabouin JJ, Shinohara ET, Moretti L, Yang
ES, Kaminski JM and Lu B: The role of mTOR inhibition in augmenting
radiation induced autophagy. Technol Cancer Res Treat. 6:443–447.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saunders P, Cisterne A, Weiss J, Bradstock
KF and Bendall LJ: The mammalian target of rapamycin inhibitor
RAD001 (everolimus) synergizes with chemotherapeutic agents,
ionizing radiation and proteasome inhibitors in pre-B acute
lymphocytic leukemia. Haematologica. 96:69–77. 2011. View Article : Google Scholar
|
|
26
|
Sukumari-Ramesh S, Singh N, Dhandapani KM
and Vender JR: mTOR inhibition reduces cellular proliferation and
sensitizes pituitary adenoma cells to ionizing radiation. Surg
Neurol Int. 2:222011. View Article : Google Scholar
|
|
27
|
Albert JM, Kim KW, Cao C and Lu B:
Targeting the Akt/mammalian target of rapamycin pathway for
radiosensitization of breast cancer. Mol Cancer Ther. 5:1183–1189.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kuwahara Y, Oikawa T, Ochiai Y, et al:
Enhancement of autophagy is a potential modality for tumors
refractory to radiotherapy. Cell Deat Dis. 2:1–11. 2011.PubMed/NCBI
|
|
29
|
Eshleman JS, Carlson BL, Madek AC, Kastner
AD, Shide L and Sarkaria JN: Inhibition of the mammalian target of
rapamycin sensitizes U87 xenografts to fractionated radiation
therapy. Cancer Res. 15:7291–7297. 2002.PubMed/NCBI
|
|
30
|
Shinohara ET, Cao C, Niermann K, Mu Y,
Zeng F, Hallahan DE and Lu B: Enhanced radiation damage of tumor
vasculature by mTOR inhibitors. Oncogene. 24:5414–5422. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bandhakavi S, Kim YM, Ro SH, et al:
Quantitative nuclear proteomics identifies mTOR regulation of DNA
damage response. Mol Cell Proteomics. 9:403–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tam KH, Yang ZF, Lam CT, Pang RW and Poon
RT: Inhibition of mTOR enhances chemosensitivity in hepatocellular
carcinoma. Cancer Lett. 273:201–209. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen H, Vanderwaal RP, Feng Z, et al: The
mTOR inhibitor rapamycin suppresses DNA double-strand break repair.
Radiat Res. 175:214–224. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu AX, Abrams TA, Miksad R, et al: Phase
1/2 study of everolimus in advanced hepatocellular carcinoma.
Cancer. 117:5094–5102. 2011. View Article : Google Scholar : PubMed/NCBI
|
